The PAM4 mAb, which recognizes a carbohydrate-induced conformational epitope on MUC1 and MUC5AC, has been evaluated as a targeting vehicle for therapy and imaging of pancreatic cancer. This evidence concerns the gene MUC5AC and familial pancreatic carcinoma.